Pharma R&D Today

Ideas and Insight supporting all stages of Drug Discovery & Development

Select category
Search this blog
Xuanyan Xu

Xuanyan Xu

Sr. Marketing Manager, Life Sciences Audience at Elsevier

Connect with Xuanyan Xu on LinkedIn
Follow Xuanyan Xu on Twitter
Website:

About the author: Seeing academic discoveries translated into life-changing applications is exciting--and, even more so, being a part of it. As a senior marketing manager for Life Sciences Audience, I bring a strong understanding of pharmaceutical industry needs, advancing technologies and customer insights to drive the product go-to-market strategy, planning and execution. Everything I write about here is geared towards issues that I deeply care about: open innovation, emerging approaches in data science and the evolving regulatory framework. Feel free to reach out to me about these topics. It is my desire to deliver my understanding and knowledge back to our communities.

Posts by Xuanyan Xu

Elsevier uses machine learning to benefit pharmacovigilance

Posted on November 7th, 2019 in Pharmacovigilance

Monitoring the scientific literature for adverse drug reactions (ADRs) is critical to maintaining drug safety, and there is no room for error. As regulations tighten, pharmacovigilance teams are seeking better strategies and methods for ensuring that all ADRs are identified in the most effective and efficient way possible.

(more…)

Elsevier research will be featured at upcoming Safety Pharmacology Society meeting

Posted on September 4th, 2019 in Pharma R&D

Network showing human adverse events that are concordant in one or more species (Source: Matthew Clark & Thomas Steiger-Hartmann, Regulatory Toxicology and Pharmacology, July 2018)

The 2019 Safety Pharmacology Society meeting will be in Barcelona from September 23-26, and the event is bringing together industry professionals to share best practices, enjoy networking opportunities, hear keynote speeches from thought leaders, and learn about hot research topics from experts in the field.

(more…)

The Beneficial Impacts of Real-World Evidence in Drug Development

Posted on August 1st, 2019 in Pharma R&D

Advances in technology, increased investment in digital solutions and the creation of more powerful analytics are all contributing to a growing interest in utilizing real-world evidence (RWE) in drug discovery & development. Following up on my previous post that goes into detail on what RWE is and why the industry is increasingly drawn to it, I now want to discuss its role and impact in the drug development life cycle.

(more…)

Why is the Pharma Industry Buzzing About Real-World Evidence?

Posted on July 30th, 2019 in Pharma R&D

You have almost certainly heard the terms Real-World Data (RWD) and Real-World Evidence (RWE) – but are you still unsure about exactly what these things are and why they’re important? Let’s break it down.

(more…)

  1. 1
  2. 2
  3. 3
  4. 4